Opdivo Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to Placebo in the Adjuvant Setting Biotech Investing
Opdivo Plus Chemotherapy Demonstrated Significant Overall and Progression-Free Survival Benefits Versus Chemotherapy in First-Line Treatment of Gastric and Esophageal Cancers Biotech Investing
Merck's KEYTRUDA® Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer Pharmaceutical Investing
Abbott Receives CE Mark for Next-Generation MitraClip Heart Valve Repair Device to Treat Mitral Regurgitation Medical Device Investing
First-Line Treatment With Merck's KEYTRUDA® Doubled Five-Year Survival Rate Versus Chemotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Pharmaceutical Investing
Bausch Health To Acquire Option To Purchase All Ophthalmology Assets Of Allegro Ophthalmics Medical Device Investing
LYNPARZA® Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
LYNPARZA® Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer Pharmaceutical Investing
